{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:20:56Z","timestamp":1786335656016,"version":"build-2736575974"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,14]]},"DOI":"10.7759\/cureus.69416","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T18:40:19Z","timestamp":1726339219000},"source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Atopic Dermatitis in Children"],"prefix":"10.7759","author":[{"given":"Faten","family":"Sid Idris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier W","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020, 101:590-598.","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider L","year":"2013","unstructured":"Schneider L, Tilles S, Lio P, et al.. Atopic dermatitis: a practice parameter update 2012. Allergy Clin Immunol. 2013, 131:295-299. 10.1016\/j.jaci.2012.12.672","journal-title":"Allergy Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2014.35.3798","article-title":"Atopic dermatitis: the updated practice parameter and beyond","volume":"35","author":"Boguniewicz M","year":"2014","unstructured":"Boguniewicz M. Atopic dermatitis: the updated practice parameter and beyond. Allergy Asthma Proc. 2014, 35:429-434. 10.2500\/aap.2014.35.3798","journal-title":"Allergy Asthma Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury R","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, et al.. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014, 71:327-349. 10.1016\/j.jaad.2014.03.030","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield LF","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al.. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014, 70:338-351. 10.1016\/j.jaad.2013.10.010","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz M","year":"2011","unstructured":"Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011, 242:233-246. 10.1111\/j.1600-065X.2011.01027.x","journal-title":"Immunol Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2019.02.180225","article-title":"The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC consortium","volume":"32","author":"Al-Naqeeb J","year":"2019","unstructured":"Al-Naqeeb J, Danner S, Fagnan LJ, et al.. The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC consortium. J Am Board Fam Med. 2019, 32:191-200. 10.3122\/jabfm.2019.02.180225","journal-title":"J Am Board Fam Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt EB","year":"2011","unstructured":"Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011, 2:10.4172\/2155-9899.1000110","journal-title":"J Clin Cell Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.02.006","article-title":"An update on the pathophysiology of atopic dermatitis","volume":"35","author":"Malik K","year":"2017","unstructured":"Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017, 35:317-326. 10.1016\/j.det.2017.02.006","journal-title":"Dermatol Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.036","article-title":"Atopic dermatitis: pathogenesis","volume":"36","author":"Guttman-Yassky E","year":"2017","unstructured":"Guttman-Yassky E, Waldman A, Ahluwalia J, Ong PY, Eichenfield LF. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017, 36:100-103. 10.12788\/j.sder.2017.036","journal-title":"Semin Cutan Med Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein AB","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020, 8:91-101. 10.1016\/j.jaip.2019.06.044","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.035","article-title":"A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics","volume":"80","author":"Yew YW","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019, 80:390-401. 10.1016\/j.jaad.2018.09.035","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2016.08.007","article-title":"Itch in atopic dermatitis","volume":"37","author":"Kido-Nakahara M","year":"2017","unstructured":"Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in atopic dermatitis. Immunol Allergy Clin North Am. 2017, 37:113-122. 10.1016\/j.iac.2016.08.007","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7","article-title":"The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus","volume":"37","author":"Rerknimitr P","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017, 37:14. 10.1186\/s41232-017-0044-7","journal-title":"Inflamm Regen"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.alit.2016.12.002","article-title":"Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies","volume":"66","author":"Furue M","year":"2017","unstructured":"Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, Kadono T. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017, 66:398-403.","journal-title":"Allergol Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3847","article-title":"Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade","volume":"4","author":"Leyva-Castillo JM","year":"2013","unstructured":"Leyva-Castillo JM, Hener P, Michea P, Karasuyama H, Chan S, Soumelis V, Li M. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. Nat Commun. 2013, 4:2847. 10.1038\/ncomms3847","journal-title":"Nat Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf4918","article-title":"A central neural circuit for itch sensation","volume":"357","author":"Mu D","year":"2017","unstructured":"Mu D, Deng J, Liu KF, et al.. A central neural circuit for itch sensation. Science. 2017, 357:695-699. 10.1126\/science.aaf4918","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12317","article-title":"Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications","volume":"41","author":"Tominaga M","year":"2014","unstructured":"Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. 2014, 41:205-212. 10.1111\/1346-8138.12317","journal-title":"J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00058.x","article-title":"The differential diagnosis of atopic dermatitis in childhood","volume":"19","author":"Krol A","year":"2006","unstructured":"Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther. 2006, 19:73-82. 10.1111\/j.1529-8019.2006.00058.x","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.9.1119","article-title":"Dermatitis and the newborn rash of hyper-IgE syndrome","volume":"140","author":"Eberting CL","year":"2004","unstructured":"Eberting CL, Davis J, Puck JM, Holland SM, Turner ML. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol. 2004, 140:1119-1125. 10.1001\/archderm.140.9.1119","journal-title":"Arch Dermatol"},{"key":"ref21","article-title":"Management of atopic eczema in primary care","volume":"15","author":"Azizan NZ","year":"2020","unstructured":"Azizan NZ, Ambrose D, Sabeera B, et al.. Management of atopic eczema in primary care. Malays Fam Physician. 2020, 15:39-43.","journal-title":"Malays Fam Physician"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14667","article-title":"Interventions to improve primary care provider management of atopic dermatitis: a systematic review","volume":"38","author":"Croce EA","year":"2021","unstructured":"Croce EA, Lopes FC, Ruth J, Silverberg JI. Interventions to improve primary care provider management of atopic dermatitis: a systematic review. Pediatr Dermatol. 2021, 38:1004-1011. 10.1111\/pde.14667","journal-title":"Pediatr Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.06.073","article-title":"Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States","volume":"163","author":"Saavedra JM","year":"2013","unstructured":"Saavedra JM, Boguniewicz M, Chamlin S, et al.. Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States. J Pediatr. 2013, 163:1747-1753. 10.1016\/j.jpeds.2013.06.073","journal-title":"J Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12590","article-title":"Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman CR","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013, 169:1326-1332. 10.1111\/bjd.12590","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.055","article-title":"Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative","volume":"82","author":"Leshem YA","year":"2020","unstructured":"Leshem YA, Chalmers JR, Apfelbacher C, et al.. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. J Am Acad Dermatol. 2020, 82:1181-1186. 10.1016\/j.jaad.2019.12.055","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00499-x","article-title":"Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting","volume":"24","author":"Eichenfield LF","year":"2022","unstructured":"Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs. 2022, 24:293-305. 10.1007\/s40272-022-00499-x","journal-title":"Paediatr Drugs"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"Kunz B","year":"1997","unstructured":"Kunz B, Oranje AP, Labr\u00e8ze L, Stalder JF, Ring J, Ta\u00efeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997, 195:10-19. 10.1159\/000245677","journal-title":"Dermatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02577.x","article-title":"Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe","volume":"66","author":"Stalder JF","year":"2011","unstructured":"Stalder JF, Barbarot S, Wollenberg A, et al.. Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011, 66:1114-1121. 10.1111\/j.1398-9995.2011.02577.x","journal-title":"Allergy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura M","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016, 74:288-294. 10.1016\/j.jaad.2015.09.062","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective","volume":"140","author":"Charman CR","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004, 140:1513-1519. 10.1001\/archderm.140.12.1513","journal-title":"Arch Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang V","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021, 126:3-12. 10.1016\/j.anai.2020.08.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1111\/j.1525-1470.2005.22303.x","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society","volume":"22","author":"Carroll CL","year":"2005","unstructured":"Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005, 22:192-199.","journal-title":"Pediatr Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2017.38.4005","article-title":"Atopic dermatitis: burden of illness, quality of life, and associated complications","volume":"38","author":"Drucker AM","year":"2017","unstructured":"Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017, 38:3-8. 10.2500\/aap.2017.38.4005","journal-title":"Allergy Asthma Proc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-6712.2007.00547.x","article-title":"Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study","volume":"22","author":"Magin P","year":"2008","unstructured":"Magin P, Adams J, Heading G, Pond D, Smith W. Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study. Scand J Caring Sci. 2008, 22:430-436. 10.1111\/j.1471-6712.2007.00547.x","journal-title":"Scand J Caring Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.031","article-title":"Patient perspectives on the management of atopic dermatitis","volume":"118","author":"Zuberbier T","year":"2006","unstructured":"Zuberbier T, Orlow SJ, Paller AS, et al.. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006, 118:226-232. 10.1016\/j.jaci.2006.02.031","journal-title":"J Allergy Clin Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1160-7","article-title":"Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey","volume":"17","author":"Lee S","year":"2017","unstructured":"Lee S, Shin A. Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry. 2017, 17:3. 10.1186\/s12888-016-1160-7","journal-title":"BMC Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.03.023","article-title":"Association of atopic dermatitis with suicide risk among 788,411 adolescents: a Korean cross-sectional study","volume":"125","author":"Kyung Y","year":"2020","unstructured":"Kyung Y, Choi MH, Jeon YJ, Lee JS, Lee JH, Jo SH, Kim SH. Association of atopic dermatitis with suicide risk among 788,411 adolescents: a Korean cross-sectional study. Ann Allergy Asthma Immunol. 2020, 125:55-64. 10.1016\/j.anai.2020.03.023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000582","article-title":"Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u201cI\u2019m tired, overwhelmed, and feel like I\u2019m failing as a mother\u201d","volume":"31","author":"Capozza K","year":"2020","unstructured":"Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u201cI\u2019m tired, overwhelmed, and feel like I\u2019m failing as a mother\u201d. Dermatitis. 2020, 31:223-227. 10.1097\/DER.0000000000000582","journal-title":"Dermatitis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1590\/1984-0462\/;2017;35;1;00006","article-title":"Impact of atopic dermatitis on the quality of life of pediatric patients and their guardians","volume":"35","author":"Campos AL","year":"2017","unstructured":"Campos AL, Ara\u00fajo FM, Santos MA, Santos AA, Pires CA. Impact of atopic dermatitis on the quality of life of pediatric patients and their guardians. Rev Paul Pediatr. 2017, 35:5-10. 10.1590\/1984-0462\/;2017;35;1;00006","journal-title":"Rev Paul Pediatr"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-020-0777-9","article-title":"Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach \u2014 summary document from an Italian expert group","volume":"46","author":"El Hachem M","year":"2020","unstructured":"El Hachem M, Di Mauro G, Rotunno R, et al.. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach \u2014 summary document from an Italian expert group. Ital J Pediatr. 2020, 46:11. 10.1186\/s13052-020-0777-9","journal-title":"Ital J Pediatr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part\u00a0II","volume":"32","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al.. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part\u00a0II. J Eur Acad Dermatol Venereol. 2018, 32:850-878. 10.1111\/jdv.14888","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-016-0229-8","article-title":"Consensus conference on clinical management of pediatric atopic dermatitis","volume":"42","author":"Galli E","year":"2016","unstructured":"Galli E, Neri I, Ricci G, et al.. Consensus conference on clinical management of pediatric atopic dermatitis. Ital J Pediatr. 2016, 42:26. 10.1186\/s13052-016-0229-8","journal-title":"Ital J Pediatr"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212530","article-title":"Emollient treatment of atopic dermatitis: latest evidence and clinical considerations","volume":"7","author":"Hon KL","year":"2018","unstructured":"Hon KL, Kung JS, Ng WG, Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018, 7:212530. 10.7573\/dic.212530","journal-title":"Drugs Context"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.07.060","article-title":"Application of moisturizer to neonates prevents development of atopic dermatitis","volume":"134","author":"Horimukai K","year":"2014","unstructured":"Horimukai K, Morita K, Narita M, et al.. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014, 134:824-830.e6. 10.1016\/j.jaci.2014.07.060","journal-title":"J Allergy Clin Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.005","article-title":"Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention","volume":"134","author":"Simpson EL","year":"2014","unstructured":"Simpson EL, Chalmers JR, Hanifin JM, et al.. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014, 134:818-823. 10.1016\/j.jaci.2014.08.005","journal-title":"J Allergy Clin Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012119.pub2","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"van Zuuren EJ","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BW. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017, 2:CD012119. 10.1002\/14651858.CD012119.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2009.00422.x","article-title":"An evaluation of prescription device moisturizers","volume":"8","author":"Draelos ZD","year":"2009","unstructured":"Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009, 8:40-43. 10.1111\/j.1473-2165.2009.00422.x","journal-title":"J Cosmet Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield LF","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al.. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014, 71:116-132. 10.1016\/j.jaad.2014.03.023","journal-title":"J Am Acad Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang JT","year":"2009","unstructured":"Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009, 123:e808-e814. 10.1542\/peds.2008-2217","journal-title":"Pediatrics"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2016.08.003","article-title":"Wet wrap therapy in moderate to severe atopic dermatitis","volume":"37","author":"Nicol NH","year":"2017","unstructured":"Nicol NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis. Immunol Allergy Clin North Am. 2017, 37:123-139. 10.1016\/j.iac.2016.08.003","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2018.8.e41","article-title":"A clinician's reference guide for the management of atopic dermatitis in Asians","volume":"8","author":"Chow S","year":"2018","unstructured":"Chow S, Seow CS, Dizon MV, et al.. A clinician's reference guide for the management of atopic dermatitis in Asians. Asia Pac Allergy. 2018, 8:e41. 10.5415\/apallergy.2018.8.e41","journal-title":"Asia Pac Allergy"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.003","article-title":"Japanese guidelines for atopic dermatitis 2017","volume":"66","author":"Katayama I","year":"2017","unstructured":"Katayama I, Aihara M, Ohya Y, et al.. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017, 66:230-247. 10.1016\/j.alit.2016.12.003","journal-title":"Allergol Int"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12065","article-title":"Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective","volume":"40","author":"Rubel D","year":"2013","unstructured":"Rubel D, Thirumoorthy T, Soebaryo RW, et al.. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013, 40:160-171. 10.1111\/1346-8138.12065","journal-title":"J Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.5.563","article-title":"Consensus guidelines for the treatment of atopic dermatitis in Korea (part I): general management and topical treatment","volume":"27","author":"Kim JE","year":"2015","unstructured":"Kim JE, Kim HJ, Lew BL, et al.. Consensus guidelines for the treatment of atopic dermatitis in Korea (part I): general management and topical treatment. Ann Dermatol. 2015, 27:563-577. 10.5021\/ad.2015.27.5.563","journal-title":"Ann Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2012.09.002","article-title":"Management of difficult-to-treat atopic dermatitis","volume":"1","author":"Arkwright PD","year":"2013","unstructured":"Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013, 1:142-151. 10.1016\/j.jaip.2012.09.002","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref56","article-title":"Moisturizers for patients with atopic dermatitis","volume":"31","author":"Varothai S","year":"2013","unstructured":"Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol. 2013, 31:91-98.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0186-1","article-title":"Comparison of the simple patient-centric atopic dermatitis scoring system pest with SCORAD in young children using a ceramide dominant therapeutic moisturizer","volume":"7","author":"Koh MJ","year":"2017","unstructured":"Koh MJ, Giam YC, Liew HM, et al.. Comparison of the simple patient-centric atopic dermatitis scoring system pest with SCORAD in young children using a ceramide dominant therapeutic moisturizer. Dermatol Ther (Heidelb). 2017, 7:383-393. 10.1007\/s13555-017-0186-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0209-1","article-title":"Complementary and alternative medicine for atopic dermatitis: an evidence-based review","volume":"17","author":"Vieira BL","year":"2016","unstructured":"Vieira BL, Lim NR, Lohman ME, Lio PA. Complementary and alternative medicine for atopic dermatitis: an evidence-based review. Am J Clin Dermatol. 2016, 17:557-581. 10.1007\/s40257-016-0209-1","journal-title":"Am J Clin Dermatol"},{"key":"ref59","article-title":"A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis","volume":"35","author":"Chan YC","year":"2006","unstructured":"Chan YC, Tay YK, Sugito TL, et al.. A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis. Ann Acad Med Singap. 2006, 35:794-803.","journal-title":"Ann Acad Med Singap"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15197","article-title":"Emollient prescribing formularies and guidelines in England, 2021: a cross-sectional study","volume":"47","author":"Amakye NY","year":"2022","unstructured":"Amakye NY, Chan J, Ridd MJ. Emollient prescribing formularies and guidelines in England, 2021: a cross-sectional study. Clin Exp Dermatol. 2022, 47:1502-1507. 10.1111\/ced.15197","journal-title":"Clin Exp Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13392","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2016","volume":"43","author":"Saeki H","year":"2016","unstructured":"Saeki H, Nakahara T, Tanaka A, et al.. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol. 2016, 43:1117-1145. 10.1111\/1346-8138.13392","journal-title":"J Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2812","article-title":"Atopic dermatitis: skin-directed management","volume":"134","author":"Tollefson MM","year":"2014","unstructured":"Tollefson MM, Bruckner AL. Atopic dermatitis: skin-directed management. Pediatrics. 2014, 134:e1735-e1744. 10.1542\/peds.2014-2812","journal-title":"Pediatrics"},{"key":"ref63","article-title":"Scoping Systematic Review of Treatments for Eczema","author":"Nankervis H","year":"2016","unstructured":"Nankervis H, Thomas KS, Delamere FM, Barbarot S, Rogers NK, Williams HC. Scoping Systematic Review of Treatments for Eczema. NIHR Journals Library, Southampton; 2016."},{"key":"ref64","doi-asserted-by":"crossref","DOI":"10.3310\/hta4370","article-title":"Systematic review of treatments for atopic eczema","volume":"4","author":"Hoare C","year":"2000","unstructured":"Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000, 4:1-191.","journal-title":"Health Technol Assess"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2015.06.004","article-title":"Taiwanese Dermatological Association consensus for the management of atopic dermatitis","volume":"33","author":"Chu CY","year":"2015","unstructured":"Chu CY, Lee CH, Shih IH, et al.. Taiwanese Dermatological Association consensus for the management of atopic dermatitis. Dermatol Sin. 2015, 33:220-230. 10.1016\/j.dsi.2015.06.004","journal-title":"Dermatol Sin"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt J","year":"2011","unstructured":"Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011, 164:415-428. 10.1111\/j.1365-2133.2010.10030.x","journal-title":"Br J Dermatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-016-0607-9","article-title":"Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis","volume":"16","author":"Siegfried EC","year":"2016","unstructured":"Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016, 16:75. 10.1186\/s12887-016-0607-9","journal-title":"BMC Pediatr"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903401470","article-title":"Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials","volume":"21","author":"Chen SL","year":"2010","unstructured":"Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010, 21:144-156. 10.3109\/09546630903401470","journal-title":"J Dermatolog Treat"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.12.038","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies","volume":"52","author":"Paller AS","year":"2005","unstructured":"Paller AS, Lebwohl M, Fleischer AB Jr, et al.. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005, 52:810-822. 10.1016\/j.jaad.2004.12.038","journal-title":"J Am Acad Dermatol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08813.x","article-title":"Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study","volume":"159","author":"Tha\u00e7i D","year":"2008","unstructured":"Tha\u00e7i D, Reitamo S, Gonzalez Ensenat MA, et al.. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008, 159:1348-1356. 10.1111\/j.1365-2133.2008.08813.x","journal-title":"Br J Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.009","article-title":"Current guidelines for the evaluation and management of atopic dermatitis: a\u00a0comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines","volume":"139","author":"Eichenfield LF","year":"2017","unstructured":"Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a\u00a0comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017, 139:S49-S57. 10.1016\/j.jaci.2017.01.009","journal-title":"J Allergy Clin Immunol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya R","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021, 148:927-940. 10.1016\/j.jaci.2021.08.009","journal-title":"J Allergy Clin Immunol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061392","article-title":"Current insights into immunology and Novel Therapeutics of atopic dermatitis","volume":"10","author":"Kader HA","year":"2021","unstructured":"Kader HA, Azeem M, Jwayed SA, et al.. Current insights into immunology and Novel Therapeutics of atopic dermatitis. Cells. 2021, 10:1392. 10.3390\/cells10061392","journal-title":"Cells"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al.. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018, 32:657-682. 10.1111\/jdv.14891","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.32.1844","article-title":"Phosphodiesterase 3 and 4 negatively regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by prostaglandin E2","volume":"32","author":"Noh AL","year":"2009","unstructured":"Noh AL, Yang M, Lee JM, Park H, Lee DS, Yim M. Phosphodiesterase 3 and 4 negatively regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by prostaglandin E2. Biol Pharm Bull. 2009, 32:1844-1848. 10.1248\/bpb.32.1844","journal-title":"Biol Pharm Bull"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.04.002","article-title":"Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes","volume":"16","author":"Jimenez JL","year":"2004","unstructured":"Jimenez JL, I\u00f1iguez MA, Mu\u00f1oz-Fern\u00e1ndez MA, Fresno M. Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal. 2004, 16:1363-1373. 10.1016\/j.cellsig.2004.04.002","journal-title":"Cell Signal"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0008","article-title":"Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis","volume":"155","author":"Yang H","year":"2019","unstructured":"Yang H, Wang J, Zhang X, Zhang Y, Qin ZL, Wang H, Luo XY. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019, 155:585-593. 10.1001\/jamadermatol.2019.0008","journal-title":"JAMA Dermatol"},{"key":"ref78","unstructured":"Eucrisa (crisaborole). Uses, Side Effects, Dosage & Reviews . (2020). Accessed: February 7, 2022: https:\/\/www.goodrx.com\/eucrisa\/what-is."},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to","volume":"21","author":"Schlessinger J","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, et al.. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to. Am J Clin Dermatol. 2020, 21:275-284. 10.1007\/s40257-020-00510-6","journal-title":"Am J Clin Dermatol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller AS","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, et al.. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016, 75:494-503.e6. 10.1016\/j.jaad.2016.05.046","journal-title":"J Am Acad Dermatol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.054","article-title":"A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor","volume":"80","author":"Pao-Ling Lin C","year":"2019","unstructured":"Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019, 80:1451-1453. 10.1016\/j.jaad.2018.10.054","journal-title":"J Am Acad Dermatol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky W","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017, 76:736-744. 10.1016\/j.jaad.2016.12.005","journal-title":"J Am Acad Dermatol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao L","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013, 2:e24137. 10.4161\/jkst.24137","journal-title":"JAKSTAT"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi K","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, et al.. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011, 186:4234-4243. 10.4049\/jimmunol.1003668","journal-title":"J Immunol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto A","year":"2018","unstructured":"Tanimoto A, Shinozaki Y, Yamamoto Y, et al.. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Dermatol. 2018, 27:22-29. 10.1111\/exd.13370","journal-title":"Exp Dermatol"},{"key":"ref86","unstructured":"XELJANZ\u00ae (tofacitinib). Highlights of Prescribing Information. (2020). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203214s026lbl.pdf."},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy LL","year":"2015","unstructured":"Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015, 73:395-399. 10.1016\/j.jaad.2015.06.045","journal-title":"J Am Acad Dermatol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.12.016","article-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","volume":"4","author":"Morris GM","year":"2018","unstructured":"Morris GM, Nahmias ZP, Kim BS. Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor. JAAD Case Rep. 2018, 4:515-517. 10.1016\/j.jdcr.2017.12.016","journal-title":"JAAD Case Rep"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3325","article-title":"Atopic dermatitis: tofacitinib, an option for refractory disease","volume":"8","author":"Ferreira SB","year":"2020","unstructured":"Ferreira SB, Ferreira RB, Scheinberg MA. Atopic dermatitis: tofacitinib, an option for refractory disease. Clin Case Rep. 2020, 8:3244-3247. 10.1002\/ccr3.3325","journal-title":"Clin Case Rep"},{"key":"ref90","unstructured":"US Food and Drug Administration. JAKAFI\u00ae (ruxolitinib). Highlights of Prescribing Information. (2019). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202192s017lbl.pdf."},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.501","article-title":"Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Blauvelt A","year":"2021","unstructured":"Blauvelt A, Szepietowski JC, Papp KA, et al.. Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies. J Eur Acad Dermatol . 2021, 85:AB121. 10.1016\/j.jaad.2021.06.501","journal-title":"J Eur Acad Dermatol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.727","article-title":"Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Simpson EL","year":"2021","unstructured":"Simpson EL, Augustin M, Thaci D, et al.. Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021, 85:AB178. 10.1016\/j.jaad.2021.06.727","journal-title":"J Am Acad Dermatol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.25251\/skin.4.supp.95","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two Phase 3, randomised, double-blind studies","volume":"4","author":"Papp K","year":"2020","unstructured":"Papp K, Szepietowski JC, Kircik L, et al.. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two Phase 3, randomised, double-blind studies. SKIN: J Cutan Med. 2020, 4:s95. 10.25251\/skin.4.supp.95","journal-title":"SKIN: J Cutan Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.supp.67","article-title":"Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies","volume":"5","author":"Simpson EL","year":"2021","unstructured":"Simpson EL, Boguniewicz M, Thaci D, et al.. Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies. SKIN: J Cutan Med. 2021, 5:s67. 10.25251\/skin.5.supp.67","journal-title":"SKIN: J Cutan Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00734-8","article-title":"Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies","volume":"24","author":"Bloudek L","year":"2023","unstructured":"Bloudek L, Eichenfield LF, Silverberg JI, et al.. Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies. Am J Clin Dermatol. 2023, 24:109-117. 10.1007\/s40257-022-00734-8","journal-title":"Am J Clin Dermatol"},{"key":"ref96","unstructured":"JT Receives Manufacturing and Marketing Approval of CORECTIM\u00ae Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan. (2020). https.\/\/www.jt.com\/media\/news\/2020\/pdf\/20200123_E01.pdf."},{"key":"ref97","unstructured":"JT receives approvals of CORECTIM\u00ae ointment 0.25% and. (2021). https.\/\/www.jt.com\/media\/news\/2021\/pdf\/20210323_E1.pdf."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm M","year":"2020","unstructured":"Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TS. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020, 182:1103-1110. 10.1111\/bjd.18469","journal-title":"Br J Dermatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.504","article-title":"A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the hand eczema severity index (HECSI)","volume":"85","author":"Soerensen P","year":"2021","unstructured":"Soerensen P, Griffiths P, Sch\u00fcett T, Larsen LS, Resen K, Agner T. A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the hand eczema severity index (HECSI). J Am Acad Dermatol. 2021, 85:AB121. 10.1016\/j.jaad.2021.06.504","journal-title":"J Am Acad Dermatol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa H","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H, Nagata T. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020, 47:114-120. 10.1111\/1346-8138.15173","journal-title":"J Dermatol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa H","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, Nagata T. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021, 85:854-862. 10.1016\/j.jaad.2021.06.014","journal-title":"J Am Acad Dermatol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis MN","year":"2022","unstructured":"Landis MN, Arya M, Smith S, et al.. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol. 2022, 187:878-887. 10.1111\/bjd.21826","journal-title":"Br J Dermatol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.770","article-title":"Safety of ATI-502, a novel topical JAK1\/3 inhibitor, in adults with moderate to severe atopic dermatitis: results from a phase 2a open-label trial","volume":"83","author":"Smith S","year":"2020","unstructured":"Smith S, Bhatia N, Shanler SD, DeMoor R, Schnyder J. Safety of ATI-502, a novel topical JAK1\/3 inhibitor, in adults with moderate to severe atopic dermatitis: results from a phase 2a open-label trial. J Am Acad Dermatol . 2020, 83:170. 10.1016\/j.jaad.2020.06.770","journal-title":"J Am Acad Dermatol"},{"key":"ref104","unstructured":"OLUMIANT\u00ae (baricitinib). Highlights of Prescribing Information. (2018). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf."},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich K","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al.. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020, 156:1333-1343. 10.1001\/jamadermatol.2020.3260","journal-title":"JAMA Dermatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.335","article-title":"Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib","volume":"85","author":"Gooderham M","year":"2021","unstructured":"Gooderham M, Weisman J, Goldblum O, Brinker D, Issa M, Reich K. Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib. J Am Acad Dermatol. 2021, 85:77. 10.1016\/j.jaad.2021.06.335","journal-title":"J Am Acad Dermatol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials","volume":"22","author":"King B","year":"2021","unstructured":"King B, Maari C, Lain E, et al.. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021, 22:395-405. 10.1007\/s40257-021-00602-x","journal-title":"Am J Clin Dermatol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000725","article-title":"Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib","volume":"32","author":"Simpson EL","year":"2021","unstructured":"Simpson EL, Wollenberg A, Bissonnette R, et al.. Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis. 2021, 32:S53-S61. 10.1097\/DER.0000000000000725","journal-title":"Dermatitis"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4551","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"156","author":"Gooderham MJ","year":"2020","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al.. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2020, 156:104. 10.1001\/jamadermatol.2019.4551","journal-title":"JAMA Dermatol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette R","year":"2019","unstructured":"Bissonnette R, Maari C, Forman S, et al.. The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019, 181:733-742. 10.1111\/bjd.17932","journal-title":"Br J Dermatol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis","volume":"156","author":"Drucker AM","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, et al.. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020, 156:659-667. 10.1001\/jamadermatol.2020.0796","journal-title":"JAMA Dermatol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz M","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018, 120:10-22.e2. 10.1016\/j.anai.2017.10.039","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419882654","article-title":"Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section IV: consensus statements on the assessment and management of pediatric atopic dermatitis","volume":"23","author":"Lansang P","year":"2019","unstructured":"Lansang P, Lara-Corrales I, Bergman JN, et al.. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section IV: consensus statements on the assessment and management of pediatric atopic dermatitis. J Cutan Med Surg. 2019, 23:32S-39S. 10.1177\/1203475419882654","journal-title":"J Cutan Med Surg"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00342-w","article-title":"New and emerging therapies for pediatric atopic dermatitis","volume":"21","author":"Nguyen HL","year":"2019","unstructured":"Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019, 21:239-260. 10.1007\/s40272-019-00342-w","journal-title":"Paediatr Drugs"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller AS","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al.. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020, 83:1282-1293. 10.1016\/j.jaad.2020.06.054","journal-title":"J Am Acad Dermatol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2038","article-title":"Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care","volume":"15","author":"Francis NA","year":"2017","unstructured":"Francis NA, Ridd MJ, Thomas-Jones E, et al.. Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med. 2017, 15:124-130. 10.1370\/afm.2038","journal-title":"Ann Fam Med"},{"key":"ref117","unstructured":"Overview | Atopic eczema in under 12s | Quality standards | NICE . (2013). Accessed. August 27, 2020: https:\/\/www.nice.org.uk\/guidance\/QS44."},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003871.pub3","article-title":"Interventions to reduce Staphylococcus aureus in the management of eczema","volume":"2019","author":"George SM","year":"2019","unstructured":"George SM, Karanovic S, Harrison DA, et al.. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019, 2019:CD003871. 10.1002\/14651858.CD003871.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S163814","article-title":"Treatment-resistant atopic dermatitis: challenges and solutions","volume":"12","author":"Johnson BB","year":"2019","unstructured":"Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019, 12:181-192. 10.2147\/CCID.S163814","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson EL","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al.. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016, 375:2335-2348. 10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck LA","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al.. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014, 371:130-139. 10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al.. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017, 10:2287-2303. 10.1016\/S0140-6736(17)31191-1","journal-title":"Lancet"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Yu SH","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018, 78:733-740.e11. 10.1016\/j.jaad.2017.09.074","journal-title":"J Am Acad Dermatol"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker AM","year":"2018","unstructured":"Drucker AM, Eyerich K, de Bruin-Weller MS, et al.. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018, 178:768-775. 10.1111\/bjd.15928","journal-title":"Br J Dermatol"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag KG","year":"1994","unstructured":"Saag KG, Koehnke R, Caldwell JR, et al.. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994, 96:115-123. 10.1016\/0002-9343(94)90131-7","journal-title":"Am J Med"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt","volume":"172","author":"El-Khalawany MA","year":"2013","unstructured":"El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013, 172:351-356. 10.1007\/s00431-012-1893-3","journal-title":"Eur J Pediatr"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1227420","article-title":"Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis","volume":"28","author":"Thijs JL","year":"2017","unstructured":"Thijs JL, Van Der Geest BA, Van Der Schaft J, et al.. Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J Dermatolog Treat. 2017, 28:242-245. 10.1080\/09546634.2016.1227420","journal-title":"J Dermatolog Treat"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram ME","year":"2011","unstructured":"Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011, 128:353-359. 10.1016\/j.jaci.2011.03.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch E","year":"2014","unstructured":"Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014, 133:429-438. 10.1016\/j.jaci.2013.07.049","journal-title":"J Allergy Clin Immunol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310013388","article-title":"Acute and maintenance treatment of atopic dermatitis in children \u2014 two comparative studies with fluticasone propionate (0.05%) cream","volume":"14","author":"Kirkup ME","year":"2003","unstructured":"Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children \u2014 two comparative studies with fluticasone propionate (0.05%) cream. J Dermatolog Treat. 2003, 14:141-148. 10.1080\/09546630310013388","journal-title":"J Dermatolog Treat"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.679","article-title":"The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: a randomized controlled trial","volume":"8","author":"Mansour NO","year":"2020","unstructured":"Mansour NO, Mohamed AA, Hussein M, et al.. The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: a randomized controlled trial. Pharmacol Res Perspect. 2020, 8:e00679. 10.1002\/prp2.679","journal-title":"Pharmacol Res Perspect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268239-treatment-of-atopic-dermatitis-in-children","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T18:40:29Z","timestamp":1726339229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268239-treatment-of-atopic-dermatitis-in-children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":131,"URL":"https:\/\/doi.org\/10.7759\/cureus.69416","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}